India, Oct. 2 -- The Indian pharmaceutical industry is seeing growing opportunities in generic medicines, supported by increasing demand across regulated and emerging markets. For pharma companies, product approvals, manufacturing capacity and faster commercialisation are becoming key drivers of revenue growth.

With a market capitalisation of Rs. 6,211 cr, the shares of Senores Pharmaceuticals Ltd closed at Rs. 1348.75 per share, down from its previous close of Rs. 1,384.30 per share.

Guidance Senores Pharmaceuticals has guided for 30-40% revenue growth and 50-60% PAT growth in FY27. The key question is whether its expanding product pipeline, manufacturing capacity and new US channels can translate into commercial revenue quickly enoug...